The European First Episode Schizophrenia Trial (EUFEST): Rationale and design of the trial
Authors:
- W. Wolfgang FleischhackerWFW. Wolfgang Fleischhacker
- Ireneus P.M. KeetIKIreneus P.M. Keet
- René S. KahnRKRené S. Kahn
- 1 October 2005
- journal article
- research article
- Published by Elsevier in Schizophrenia Research
- Vol. 78 (2-3) , 147-156
Abstract
No abstract availableKeywords
This publication has 59 references indexed in Scilit:
- The safety of clozapine in the treatment of first- and multiple-episode patients with treatment-resistant schizophreniaInternational Journal of Neuropsychopharmacology, 2003
- Atypical and Conventional Antipsychotic Drugs in Treatment-Naive First-Episode Schizophrenia: A 52-Week Randomized Trial of Clozapine Vs ChlorpromazineNeuropsychopharmacology, 2003
- Substance Misuse in Patients with SchizophreniaDrugs, 2002
- Choosing the Right Dose of Antipsychotics in SchizophreniaCNS Drugs, 2001
- Molindone for schizophrenia and severe mental illness2000
- Elevated Prolactin in Pediatric Patients on Typical and Atypical AntipsychoticsJournal of Child and Adolescent Psychopharmacology, 1999
- Randomised controlled trial of compliance therapyThe British Journal of Psychiatry, 1998
- Differentiation of cognitive and motor slowing in the Digit Symbol Test (DST): differences between depression and schizophreniaJournal of Psychiatric Research, 1998
- Validating the St. Hans Rating Scale With the Abnormal Involuntary Movement Scale (AIMS) in the Assessment of Tardive DyskinesiaJournal of Clinical Psychopharmacology, 1996
- Explanatory and pragmatic attitudes in therapeutical trialsJournal of Chronic Diseases, 1967